Home / Expertise / Life Sciences & Healthcare
Lab

Life Sciences & Healthcare

United Kingdom

Discovery, innovation, market awareness and understanding are key to those life sciences and healthcare entities providing services and finance towards, and developing therapies and services for, the improvement of patient outcomes.

Due to the highly regulated nature of the industry, as an operator, investor, adviser, developer or licensee, you will be dealing with complex legal and regulatory requirements to launch, maintain and deliver your products and services to the market.

Our Life Sciences team is immersed in the sector and we appreciate our clients' technology; we are not just lawyers, we are immunologists, geneticists, chemists and engineers. With this background we are ideally placed to really understand your business, how it is changing and what you want from a trusted advisor. Highly relevant to this sector is our fully integrated European patent attorney practice. Spanning multiple disciplines, both legal and scientific, our lawyers and patent attorneys operate as one team with a common outlook and objective for our clients - providing pragmatic, innovative and effective advice, efficiently.

Our Healthcare team is truly immersed in the sector with over 25 years of advising and shaping the sector through in depth experience, knowledge and sector associations and collaborations. We have significant experience of working within the public and private sectors, giving us a complete perspective of the issues you face, allowing us to offer you commercial and well rounded advice.

With active memberships in major industry bodies such as the ABPI, ABHI, BIVDA, EUCOMED / MedTech Europe, Healthcare UK and the BPF, we help shape the legal and compliance frameworks impacting the life sciences and healthcare sectors.

As well as clients' significant, complex and strategic transactional, financing and structuring matters, we regularly advise on day-to-day business operations, covering areas such as public procurement, tax, competition, IP protection, exploitation and enforcement, product liability, supply chain, outsourcing and other commercial agreements and employment and pensions matters, as well as regulatory, disputes, risk and compliance advice. Truly a full service.

Read more Read less

"A one-stop-shop for us: its remarkable and successful mix of talent makes it stand out from the rest, and makes our lives much easier."

Chambers UK, 2015

Choose area

    Biotech

    Recent years have seen an increase in the numbers of biotech IPOs and more investment in the sector, however it can still be challenging accessing the finance necessary to fund R&D and to bring products to the market. As part of the biotech industry you will expect your lawyers to assist you in tackling these difficult financing and market challenges. Our team of sector specialists, including lawyers with technical backgrounds, understands the commercial drivers in this industry and can advise you on the full spectrum of legal matters.

    Read more

    Devices & Diagnostics

    In an increasingly competitive healthcare market, medical device and diagnostics companies need to ensure return on investment when developing innovative and reliable medical technologies and services. Devices and diagnostics are subject to complex regulatory and compliance frameworks and are often subject to competitive tendering so you will need lawyers who can reliably advise on pragmatic, compliant solutions.

    Read more

    eHealth

    With technology and digital innovation at the forefront of many advancements in the lifesciences industry and in healthcare delivery, organisations look  to consistently push boundaries to bring products and services to both the consumer and professional market. However, the regulation of ehealth solutions, devices and services is often outpaced by the novelty and innovation in the solutions themselves and at CMS, we understand the challenges this presents.

    Read more

    Healthcare

    The healthcare sector in the UK and internationally continues to experience dynamic change underpinned by significant legal reforms. As an operator, investor, funder, developer or landlord in this sector, you are facing a highly regulated environment as well as significant public scrutiny.

    With increasing potential for the independent provision of health and social care along with an ageing population and technological advances, but with tightening public budgets, operating within the health and social care sectors presents both challenges and opportunities.
     

    Read more

    Pharmaceuticals

    With ever increasing costs of gaining marketing authorisations for new drugs, fewer opportunities for blockbuster products and ongoing pressure on pricing, operating successfully in the pharmaceutical sector can be challenging. Our sector-focused team, many of whom have technical backgrounds, are able to help clients overcome these challenges and maximise the commercial opportunities.

    Read more
    equIP Life Sci­ences: from lab bench to busi­ness
    High­lights of our ex­per­i­ence in Life Sci­ences & Health­care...
    Law-Now: Lifes­ci­ences
    Vis­it Law-Now for leg­al know-how and com­ment­ary

    Feed

    Show only
    Dec 2018
    CMS Life Sci­ences & Health­care Sec­tor Group: An over­view...
    20 Feb 20
    Gov­ern­ment con­sults on UK Glob­al Tar­iff
    The UK Gov­ern­ment has launched a pub­lic con­sulta­tion on what the UK’s glob­al tar­iff re­gime should be after the end of the trans­ition peri­od with the EU. Changes be­ing con­sidered in­clude re­mov­ing small...
    CMS Ex­pert Guide to a Leg­al Roadmap to Can­nabis
    07 Feb 20
    MHRA up­dates guid­ance on with­draw­al of no­ti­fied body ser­vices (UK)
    The Medi­cines and Health­care products Reg­u­lat­ory Agency (MHRA) has re­cently is­sued guid­ance for situ­ations where a no­ti­fied body with­draws all, or part, of its ser­vices in re­la­tion to med­ic­al devices....
    06 Feb 20
    World First as AI-de­signed Drug Starts Clin­ic­al Tri­als 
    The UK-based AI drug dis­cov­ery com­pany, Ex­scien­tia, has been hailed as reach­ing a huge mile­stone: the world’s first AI-de­signed drug to enter Phase 1 clin­ic­al tri­als. Why is this a big deal? And are...
    03 Feb 20
    Court rules in fa­vour of man­u­fac­tur­ers in first met­al on met­al hip...
    Facts In the case of Hast­ings v Fins­bury Or­tho­paed­ics Ltd and Stryker UK Ltd [2019] CSOH 96, Mr Hast­ings brought a claim un­der Sec­tion 2 of the Con­sumer Pro­tec­tion Act 1987 (“the CPA”) against the...
    31 Jan 20
    UK In­tel­lec­tu­al Prop­erty Of­fice finds that pat­ent law does not cater...
    The UK In­tel­lec­tu­al Prop­erty Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The UKIPO ac­cep­ted the in­dic­a­tion...
    20 Jan 20
    Med­ic­al neg­li­gence and antenat­al care: test for breach of duty and...
    A re­cent High Court de­cision provides guid­ance on the threshold that needs to be met with re­spect to is­sues of breach and caus­a­tion in a med­ic­al neg­li­gence con­text. Facts The claimant, aged eight-and-a-half,...
    17 Jan 20
    New guid­ance on cy­ber­se­cur­ity for med­ic­al devices pub­lished
    In Decem­ber 2019, the Med­ic­al Device Co­ordin­a­tion Group (“MD­CG”) is­sued a new guid­ance to help med­ic­al device man­u­fac­tur­ers meet the cy­ber­se­cur­ity re­quire­ments in the Med­ic­al Devices Reg­u­la­tion (“MDR”)...
    15 Jan 20
    Equal­ity Act 2010 Du­ties - not just a tick box ex­er­cise
    A re­cent de­cision of the Court of Ses­sion provides guid­ance to Loc­al Au­thor­it­ies on the ap­plic­a­tion of their du­ties un­der s149 of the Equal­ity Act 2010 (the “EA 2010”) and the Equal­ity Act (Spe­cif­ic...
    15 Jan 20
    Can newly dis­covered can­nabis com­pounds be pro­tec­ted by pat­ents?
    A break­through dis­cov­ery has re­cently hit the news: tet­rahy­drocan­nabi­phorol (THCP) and can­na­bid­i­phorol (CB­DP), two new can­nabin­oid com­pounds, have been dis­covered in Can­nabis sativa and char­ac­ter­ised...
    23 Dec 19
    So­cial Me­dia and mHealth Data EMA / HMA Re­port
    New and in­nov­at­ive tech­no­lo­gies have led to a huge in­crease in data com­ing from sources that haven’t pre­vi­ously been used with­in the reg­u­lated medi­cines in­dustry. In re­cog­ni­tion of this ex­plo­sion of...